Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B3 | P37058 | 3/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.34 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.34 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.34 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.34 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 2/20 | 0.31 |
| ▸ | CNR2 | P34972 | 2/20 | 0.31 |
| ▸ | PRKCA | P17252 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8074193 | 0.88 | OPRM1 (0.39) | HSD17B3OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL13213903 | 0.80 | OPRM1 (0.42) | HSD17B3OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL13168808 | 0.80 | HSD17B3 (0.40) | HSD17B3OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL17610179 | 0.78 | CYP1A2 (0.32) | CYP1A2 | |
| SCHEMBL7097788 | 0.76 | CYP1A2 (0.42) | HSD17B3LTB4RCNR1CNR2CYP1A2 | |
| SCHEMBL27782291 | 0.75 | OPRM1 (0.39) | HSD17B3OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL7732887 | 0.74 | SLC6A4 (0.33) | HSD17B3 | |
| SCHEMBL21134598 | 0.74 | SLC6A4 (0.33) | HSD17B3 | |
| SCHEMBL21134592 | 0.74 | SLC6A4 (0.33) | HSD17B3 | |
| SCHEMBL13924884 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8318804-B2 | Antiviral activity of cyclopentene nitro-ester and derivatives | UNIVERSITY OF SOUTH FLORIDA (US) | 2012-11-27 | — | — | US | disclosed |
| US-20100249230-A1 | ANTIVIRAL ACTIVITY OF CYCLOPENTENE NITRO-ESTER AND DERIVATIVES | UNIVERSITY OF SOUTH FLORIDA (US) | 2010-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249230-A1 | ANTIVIRAL ACTIVITY OF CYCLOPENTENE NITRO-ESTER AND DERIVATIVES | CYP51A1, CES2, DDT | HSD17B3 699/4885OPRM1 782/4885OPRD1 196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.